Barclays
IOVA icon

Barclays’s Iovance Biotherapeutics IOVA Stock Holding History

Barclays’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,000
Closed -$111K – 6292
2019
Q4 		$111K Buy
+4,000
New +$91K ﹤0.01% 5424

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Barclays's IOVA Position: Q2 2026 in Review

Barclays increased its Iovance Biotherapeutics (IOVA) stake by 139% in Q2 2026, buying an estimated $334K and bringing the position to 151,112 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #3082.

Barclays first reported a position in IOVA in Q2 2015 and has held it in 44 quarters since. The position peaked at $6.8M in Q4 2023. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Barclays held 151,112 shares of Iovance Biotherapeutics worth $629K as of Q2 2026.
  • Barclays bought 87,932 Iovance Biotherapeutics shares in Q2 2026, an estimated $334K.
  • Iovance Biotherapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3082 holding.
  • Barclays first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 44 quarters since.
  • Barclays's Iovance Biotherapeutics position peaked at $6.8M in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.